MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/jjco/hyac110

Медицинская библиотека · Japanese journal of clinical oncology · 2022

Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer.

Terashima Takeshi, Morizane Chigusa, Ushiama Mineko, Shiba Satoshi, Takahashi Hideaki, Ikeda Masafumi, Mizuno Nobumasa, Tsuji Kunihiro, Yasui Kohichiroh, Azemoto Nobuaki, Satake Hironaga, Nomura Shogo, Yachida Shinichi, Sugano Kokichi, Furuse Junji

Клиническое исследование II фазыСтатьяПеревод в очереди

Аннотация

BACKGROUND

Our phase II trial (FABRIC study) failed to verify the efficacy of gemcitabine plus oxaliplatin (GEMOX) in patients with pancreatic ductal adenocarcinoma (PDAC) with a familial or personal history of pancreatic, breast, ovarian or prostate cancer, which suggested that a family and personal history may be insufficient to determine response to platinum-based chemotherapy.

METHODS

This ancillary analysis aimed to investigate the prevalence of germline variants of homologous recombination repair (HRR)-related genes and clarify the association of germline variants with the efficacy of GEMOX and patient outcome in PDAC patients. Of 45 patients enrolled in FABRIC study, 27 patients were registered in this ancillary analysis.

RESULTS

Of the identified variants in HRR-related genes, one variant was considered pathogenic and eight variants in six patients (22%) were variants of unknown significance (VUS). Objective response to GEMOX was achieved by 43% of the seven patients and tended to be higher than that of patients without such variants (25%). Pathogenic/VUS variant in HRR-related genes was an independent favorable factor for progression-free survival (hazard ratio, 0.322; P = 0.047) and overall survival (hazard ratio, 0.195; P = 0.023) in multivariable analysis.

CONCLUSIONS

The prevalence of germline variants in PDAC patients was very low even among patients with a familial/personal history of pancreatic, breast, ovarian or prostate cancer. Patients with one or more germline variants in HRR-related genes classified as pathogenic or VUS may have the potential to obtain better response to GEMOX and have better outcomes.

Для цитирования: Terashima Takeshi, Morizane Chigusa, Ushiama Mineko, Shiba Satoshi, Takahashi Hideaki, Ikeda Masafumi, Mizuno Nobumasa, Tsuji Kunihiro, Yasui Kohichiroh, Azemoto Nobuaki, Satake Hironaga, Nomura Shogo, Yachida Shinichi, Sugano Kokichi, Furuse Junji. Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer.. Japanese journal of clinical oncology. 2022. DOI: 10.1093/jjco/hyac110.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.